Application Note: Characterizing Trastuzumab ADCs with BLI and Advanced Flow Cytometry
Antibody-drug conjugates (ADCs) are among the fastest growing class of biologics and are developed as a combination of monoclonal antibodies (mAbs) and highly potent cytotoxic molecules (drugs). The antibody, in addition to its own biological specificity through its paratope, has the function of a targeted transporting tool of the drug to the targeted cell. The conjugated molecules or particles typically have cytotoxic activity and thus increase the efficiency of the antibody by an additional mechanism, leading to increased death of cells carrying the target antigen.
Conjugation of these drugs to antibodies, however, increases structural complexity which triggers the need for improved characterization methods utilizing technologies that can add biophysical and functional information.
This application note demonstrates the use of Octet® bio-layer interferometry (BLI) platform in combination with the iQue® Advanced Flow Cytometry Platform to characterize and compare the drug trastuzumab to the trastuzumab-containing reference medicinal products (RMPs) Kadcyla® and Enhertu®.
- Document type: Application Note
- Page count: 9
- Read time: 17 minutes
- Assay considerations for ADCs characterization
- Need for complimentary techniques for selection of optimal drug candidates
This Resource is Designed for:
- Drug Developers
- R&D Scientists
- Antibody discovery
- Biotherapeutics research and development
- Antibody-drug conjugates (ADCs)